title: Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate.
abstract: BACKGROUND
  Sustained virological response rates of up to 52% have been obtained with peginterferon alpha2a (40 kDa) plus ribavirin in patients suffering from chronic hepatitis C genotype 1 in randomized-controlled trials.
  
  
  OBJECTIVE
  To assess early virological response and its clinical utility in predicting an sustained virological response in patients suffering from chronic hepatitis C genotype 1 in routine clinical practice in Spain.
  
  
  METHODS
  Treatment-naïve patients received pegylated interferon alpha2a (40 kDa) 180 microg/week plus ribavirin 1000/1200 mg/day for 48 weeks, and were followed for a further 24 weeks. Overall, 475 patients received at least one dose of medication and were included in the efficacy population.
  
  
  RESULTS
  The overall sustained virological response rate was 48%. Of those with week 12 virological data, 83% had an early virological response. The negative predictive value of an early virological response was 93%.
  
  
  CONCLUSIONS
  If sustained virological response is the goal, a treatment-decision based on a 12-week evaluation during routine clinical practice is feasible.
authors.affiliation: Hospital General de Valencia, Valencia, Spain. mdiagom@meditex.es
authors.forename: M
authors.initials: M
authors.lastname: Diago
authors.forename: A
authors.initials: A
authors.lastname: Olveira
authors.forename: R
authors.initials: R
authors.lastname: Solá
authors.forename: M
authors.initials: M
authors.lastname: Romero-Gómez
authors.forename: R
authors.initials: R
authors.lastname: Moreno-Otero
authors.forename: R
authors.initials: R
authors.lastname: Pérez
authors.forename: J
authors.initials: J
authors.lastname: Salmerón
authors.forename: J
authors.initials: J
authors.lastname: Enríquez
authors.forename: R
authors.initials: R
authors.lastname: Planas
authors.forename: J C
authors.initials: JC
authors.lastname: Gavilán
authors.forename: J
authors.initials: J
authors.lastname: Del Olmo
authors.forename: R
authors.initials: R
authors.lastname: Uribarrena
authors.forename: C
authors.initials: C
authors.lastname: Sillero
authors.forename: A
authors.initials: A
authors.lastname: Benítez
authors.forename: S
authors.initials: S
authors.lastname: Sánchez-Galdón
authors.forename: B
authors.initials: B
authors.lastname: Dalmau
authors.forename: L
authors.initials: L
authors.lastname: Eraña
authors.forename: M
authors.initials: M
authors.lastname: Montoro
authors.forename: J
authors.initials: J
authors.lastname: Portu
authors.forename: J M
authors.initials: JM
authors.lastname: Garijo
authors.forename: R
authors.initials: R
authors.lastname: Barniol
authors.forename: A
authors.initials: A
authors.lastname: Domínguez
authors.forename: R
authors.initials: R
authors.lastname: Rota
authors.forename: J L
authors.initials: JL
authors.lastname: Olcoz
authors.forename: M
authors.initials: M
authors.lastname: Antón
authors.forename: X
authors.initials: X
authors.lastname: Pamplona
authors.forename: T
authors.initials: T
authors.lastname: Casanovas
authors.forename: E
authors.initials: E
authors.lastname: Jiménez
authors.forename: M
authors.initials: M
authors.lastname: Huarte
authors.forename: F
authors.initials: F
authors.lastname: Díaz
authors.forename: J
authors.initials: J
authors.lastname: Sánchez-Ruano
authors.forename: M
authors.initials: M
authors.lastname: Orive
authors.forename: M
authors.initials: M
authors.lastname: Muñoz-Sánchez
authors.forename: M
authors.initials: M
authors.lastname: Roset
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a